Medical Marijuana and Its Effects on Motor Function in People With Multiple Sclerosis
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02898974 |
|
Recruitment Status :
Completed
First Posted : September 13, 2016
Last Update Posted : January 17, 2018
|
Sponsor:
Colorado State University
Collaborator:
William R. Shaffer, M.D.
Information provided by (Responsible Party):
Thorsten Rudroff, Colorado State University
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Brief Summary:
Medical marijuana is commonly prescribed people with Multiple Sclerosis (MS) for symptom, e.g. spasticity and pain, management. Unfortunately not much is known about its effects outside the treatment for these 2 symptoms. Several previous studies have suggested people with MS using medical marijuana have lower levels of physical disability and improved walking abilities. A major limitation of these previous studies is that the investigators used subjective measures of motor function. In this proposed observational case-control study the investigators plan to objectively measure multiple domains of motor function, such as: fatigue, strength, and walking ability. No marijuana will be brought on to campus or given to participants.
| Condition or disease | Intervention/treatment |
|---|---|
| Multiple Sclerosis | Behavioral: Medical Marijuana |
To investigate the effects of medical marijuana usage on physical function the investigators will employ an observational case-control design. Cases (MS medical marijuana users) will be compared to age, sex, and disease duration matched controls (MS non-cannabis users).
| Study Type : | Observational |
| Actual Enrollment : | 19 participants |
| Observational Model: | Case-Only |
| Time Perspective: | Prospective |
| Official Title: | Medical Marijuana and Its Effects on Motor Function in People With Multiple Sclerosis: An Observational Case-control Study |
| Study Start Date : | September 2016 |
| Actual Primary Completion Date : | October 2017 |
| Actual Study Completion Date : | October 2017 |
Resource links provided by the National Library of Medicine
Genetics Home Reference related topics:
Multiple sclerosis
| Group/Cohort | Intervention/treatment |
|---|---|
|
Regular Medical Marijuana users
People with MS that are regular Medical Marijuana users
|
Behavioral: Medical Marijuana
To investigate the effects of medical marijuana usage on physical function we will employ an observational case-control design |
|
Non Users of Medical Marijuana
People with MS that are non users of Medical Marijuana
|
Primary Outcome Measures :
- Fatigue [ Time Frame: Through study completion, an average of 6 months. ]Strength decline during fatiguing muscle contraction measured with force transducer
- Muscle Strength [ Time Frame: Through study completion, an average of 6 months. ]Maximal muscle strength measured with force transducer
- Postural Stability [ Time Frame: Through study completion, an average of 6 months. ]Measured with force plates
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 30 Years to 60 Years (Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Study Population
Adults diagnosed with Multiple Sclerosis.
Criteria
Inclusion Criteria:
- Medically diagnosed with MS,
- 30-60 years of age,
- Moderate disability (Patient Determined Disease Steps score 2-6).
Exclusion Criteria:
- Relapse with the last 60 days,
- High risk for cardiovascular disease (American College of Sports Medicine risk classification),
- Changes in disease modifying medications within the last 45 days,
- Concurrent neurological/neuromuscular disease,
- Hospitalization within the last 90 days,
- Inability to understand/sign informed consent.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02898974
Locations
| United States, Colorado | |
| Department of Health and Exercise Science | |
| Fort Collins, Colorado, United States, 80523 | |
Sponsors and Collaborators
Colorado State University
William R. Shaffer, M.D.
Investigators
| Principal Investigator: | Thorsten Rudroff, Ph.D. | Colorado State University |
| Responsible Party: | Thorsten Rudroff, Assistant Professor, Colorado State University |
| ClinicalTrials.gov Identifier: | NCT02898974 History of Changes |
| Other Study ID Numbers: |
16-6685HH |
| First Posted: | September 13, 2016 Key Record Dates |
| Last Update Posted: | January 17, 2018 |
| Last Verified: | January 2018 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
Additional relevant MeSH terms:
|
Sclerosis Multiple Sclerosis Pathologic Processes Demyelinating Autoimmune Diseases, CNS Autoimmune Diseases of the Nervous System |
Nervous System Diseases Demyelinating Diseases Autoimmune Diseases Immune System Diseases |